174 related articles for article (PubMed ID: 17252556)
1. EZH2 promotes proliferation and invasiveness of prostate cancer cells.
Bryant RJ; Cross NA; Eaton CL; Hamdy FC; Cunliffe VT
Prostate; 2007 Apr; 67(5):547-56. PubMed ID: 17252556
[TBL] [Abstract][Full Text] [Related]
2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
Karanikolas BD; Figueiredo ML; Wu L
Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
5. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
Karanikolas BD; Figueiredo ML; Wu L
Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
[TBL] [Abstract][Full Text] [Related]
6. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
8. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
9. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.
Bryant RJ; Winder SJ; Cross SS; Hamdy FC; Cunliffe VT
Prostate; 2008 Feb; 68(3):255-63. PubMed ID: 18095286
[TBL] [Abstract][Full Text] [Related]
10. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
12. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
14. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
[TBL] [Abstract][Full Text] [Related]
16. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
17. PC-1/PrLZ contributes to malignant progression in prostate cancer.
Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG
Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733
[TBL] [Abstract][Full Text] [Related]
18. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
20. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
